Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8329-8338

  Yang, Yang ^a,b   Ren, Yongsheng ^a   Ramani, Vishnu C ^a   Nan, Li ^a   Suva, Larry J ^c   Sanderson, Ralph D ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; HEPARANASE; HEPARANASE ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEOGLYCAN; RECOMBINANT ENZYME; RECOMBINANT HEPARANASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW BIOPSY; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE RESORPTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMUR; FLUORESCENT ANTIBODY TECHNIQUE; GLUCURONIDASE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIBIA; UP-REGULATION;

EID: 78449276235     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2179     Document Type: Article

References (45)

1. Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. J Manag Care Pharm 2008;14:7-11.
2. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-41.
3. Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone 2008;42:1007-13.
4. Sanderson RD, Epstein J. Myeloma bone disease. J Bone Miner Res 2009;24:1783-8.
5. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-39.
6. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009;34:511-9.
7. Chen G, Dang YW, Luo DZ, Feng ZB, Tang XL. Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res 2008;17:183-9.
8. Hoffmann AC, Mori R, Vallbohmer D, et al. High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 2008;12:1674-81.
9. Cohen E, Doweck I, Naroditsky I, et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer 2008;113:1004-11.
10. Shafat I, Pode D, Peretz T, Ilan N, Vlodavsky I, Nisman B. Clinical significance of urine heparanase in bladder cancer progression. Neoplasia 2008;10:125-30.
11. Lerner I, Baraz L, Pikarsky E, et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 2008;14:668-76.
12. Cohen I, Pappo O, Elkin M, et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006;118:1609-17.
13. Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007;109:4914-23.
14. Sato T, Yamaguchi A, Goi T, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004;87:174-81.
15. Xu X, Quiros RM, Maxhimer JB, et al. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res 2003;9:5968-79.
16. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001;7:1299-305.
17. Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001;61:4655-9.
18. Yang Y, Macleod V, Bendre M, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005;105:1303-9.
19. Yang Y, Macleod V, Miao HQ, et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007;282:13326-33.
20. Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003;63:8749-56.
21. Purushothaman A, Uyama T, Kobayashi F, et al. Heparanase enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010;115:2449-57.
22. Kelly T, Suva LJ, Huang Y, et al. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 2005;65:5778-84.
23. Kelly T, Suva LJ, Nicks KM, Macleod V, Sanderson RD. Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res 2010;25:1295-304.
24. Zhou Y, Song B, Qin WJ, et al. Heparanase promotes bone destruction and invasiveness in prostate cancer. Cancer Lett 2008;268:252-9.
25. Kram V, Zcharia E, Yacoby-Zeevi O, et al. Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. J Cell Physiol 2006;207:784-92.
26. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 2000;96:2528-36.
27. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008;283:32628-36.
28. Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002;100:610-7.
29. Yang Y, MacLeod V, Dai Y, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007;110:2041-8.
30. Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999;14:1167-74.
31. Abdallah BM, Stilgren LS, Nissen N, Kassem M, Jorgensen HR, Abrahamsen B. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int 2005;76:90-7.
32. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 2009;106:2353-8.
33. T method. Nat Protoc 2008;3:1101-8.
34. Heider U, Zavrski I, Jakob C, et al. Expression of receptor activator of NF-κB ligand (RANKL) mRNA in human multiple myeloma cells. J Cancer Res Clin Oncol 2004;130:469-74.
35. Chen L, Sanderson RD. Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 2009;4:e4947.
36. Jakob C, Sterz J, Liebisch P, et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008;22:1767-72.
37. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
38. Lai FPL, Cole-Sinclair M, Cheng W-J, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004;126:192-201.
39. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90.
40. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001;98:11581-6.
41. Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003;44:1463-7.
42. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-40.
43. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-45.
44. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-κB ligand. Cancer Res 2008;68:5803-11.
45. Saijo M, Kitazawa R, Nakajima M, Kurosaka M, Maeda S, Kitazawa S. Heparanase mRNA expression during fracture repair in mice. Histochem Cell Biol 2003;120:493-503.